Seelos Therapeutics Inc (STU:NXE) Stock Price, Trades & News

Seelos Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing products that address unmet needs in Central Nervous System (CNS) disorders and other rare disorders. Its product pipeline includes SLS-002, SLS-005, SLS-004, SLS-007, and SLS-009.

Financial Strength

	Name	Current	Vs Industry		Vs History

Growth Rank

	Name	Current	Vs Industry		Vs History

Momentum Rank

	Name	Current	Vs Industry		Vs History

Liquidity Ratio

	Name	Current	Vs Industry		Vs History

Dividend & Buy Back

	Name	Current	Vs Industry		Vs History

Profitability Rank

	Name	Current	Vs Industry		Vs History

GF Value Rank

2/10

	Name	Current	Vs Industry		Vs History
	EV-to-Forward-Revenue	65.97

Financials (Next Earnings Date:2026-08-14 Est.)

Annual Quarterly TTM

STU:NXE's 30-Y Financials

AAPL

Income Statement Breakdown FY

Annual Quarterly

Not Enough Data

AAPL

Balance Sheet Breakdown

Annual Quarterly

Not Enough Data

AAPL

Cashflow Statement Breakdown

Annual Quarterly

Not Enough Data

Operating Revenue by Business Segment

Operating Revenue by Geographic Region

Historical Operating Revenue by Business Segment

Value % YoY

Historical Operating Revenue by Geographic Region

Value % YoY

See Details

5-Step DuPont Analysis as of

Annual Quarterly

Not Enough Data

Guru Trades

See Details

Insider Trades

See Details

Peter Lynch Chart

Y-axis scale:

Log Linear

Interactive Chart

Performance

Dividend

Log

Bar

Annualized Return %

Symbol	1 Week	1 Month	3 Months	6 Months	YTD	1 Year	3 Years	5 Years	10 Years

Total Annual Return %

Symbol	2026	2025	2024	2023	2022	2021	2020	2019	2018	2017

Seelos Therapeutics Inc Executives

Details

GF Value™

STU:NXE

Valuation Chart

Year:

Warning Signs

Warning! GuruFocus detected issues with NXE. Try a 7-Day Free Trial to check it out.

Analyst Estimate

Annual Quarterly

Key Statistics

	Name	Value
	Revenue (TTM) (Mil €)
	EPS (TTM) (€)	-445.322
	Beta	1.0108
	3-Year Sharpe Ratio	-0.79
	3-Year Sortino Ratio	-0.8
	Volatility %	-
	14-Day RSI	-
	14-Day ATR (€)	-
	20-Day SMA (€)	339.84
	12-1 Month Momentum %	-
	52-Week Range (€)	339.84 - 339.84
	Shares Outstanding (Mil)	0.58

Piotroski F-Score Details

Year:

	Component	Result
	Piotroski F-Score	0
	Positive ROA
	Positive CFROA
	Higher ROA yoy
	CFROA > ROA
	Lower Leverage yoy
	Higher Current Ratio yoy
	Less Shares Outstanding yoy
	Higher Gross Margin yoy
	Higher Asset Turnover yoy

Seelos Therapeutics Inc Filings

10-K10-QForm 4Others

	Filing Date	Document Date	Form
No Filing Data

Seelos Therapeutics Inc Stock Events

Financials Calendars

Event	Date	Price (€)
Third quarter earnings results for 2026	2026-11-13	In 111 days
Second quarter earnings results for 2026	2026-08-14	In 20 days
General meeting for 2025	2026-07-31	In 6 days
Annual report for 2025	2026-07-28	In 3 days
General meeting for 2024	2024-11-25 08:00	339.84 (+0.00%)
0.0625:1 Stock Split	2024-09-27	339.84 (+0.00%)
Second quarter earnings results for 2024	2024-08-14	339.84 (+0.00%)
0.125:1 Stock Split	2024-05-16	339.84 (+0.00%)
0.0333333:1 Stock Split	2023-11-28	339.84 (-24.62%)
0.033333:1 Stock Split	2019-01-24	20,275.33 (-4.86%)

Show

Entries

Seelos Therapeutics Inc Frequently Asked Questions

What is Seelos Therapeutics Inc(STU:NXE)'s stock price today?

The current price of STU:NXE is €339.84. The 52 week high of STU:NXE is €339.84 and 52 week low is €339.84.

When is next earnings date of Seelos Therapeutics Inc(STU:NXE)?

The next earnings date of Seelos Therapeutics Inc(STU:NXE) is 2026-08-14 Est..

Does Seelos Therapeutics Inc(STU:NXE) pay dividends? If so, how much?

Seelos Therapeutics Inc(STU:NXE) does not pay dividend.

Press Release

	Subject	Date
	Seelos Announces Second Postponement of its Annual Meeting of Stockholders	2024-10-24
	Seelos Therapeutics Announces Notice of Delisting from Nasdaq and Transfer of Listing to Over-the-Counter Market	2024-10-15
	Seelos Announces Postponement of its Annual Meeting of Stockholders	2024-09-26
	Seelos Therapeutics Announces 1-for-16 Reverse Stock Split	2024-09-25
	Seelos Therapeutics announces the signing of a Material Transfer Agreement with U.S. Army Medical Materiel Development Activity (USAMMDA) to evaluate SLS-002 for treatment of PTSD	2024-09-24
	Seelos Therapeutics Announces Pricing of $1.1 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules	2024-05-16
	Seelos Therapeutics Announces 1-for-8 Reverse Stock Split	2024-05-14
	Seelos Therapeutics Announces Strategic Focus on Mental Health Initiatives and Provides an Update on Current Discussions of Potential Partnerships and Collaborations	2024-04-29
	Seelos Therapeutics Provides Update on Top-Line Results from its Amyotrophic Lateral Sclerosis (ALS) Study with SLS-005 (IV Trehalose)	2024-03-19
	Seelos Therapeutics, Inc. Announces $4.0 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules	2024-01-26

10/Page

Articles on Seelos Therapeutics Inc

No articles.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.